Hot News Idera Pharma Presents Data From IMO-2125

Idera Pharmaceuticals on Saturday announced the presentation of data from the four-week Phase 1 clinical trial of IMO-2125 in combination with ribavirin in treatment-naive patients chronically infected with hepatitis C virus or HCV genotype 1.

IMO-2125 is a Toll-like receptor 9, or TLR9 agonist, which stimulates the production of natural interferon and other antiviral cytokines.

Within four weeks of treatment, IMO-2125 in combination with ribavirin was well tolerated and produced clinically significant antiviral activity, "said Idera Pharmaceuticals.

Robert Arbeit, Vice President of Clinical Development at Idera, said: "First of all, IMO-2125 in combination with ribavirin have significant antiviral activity in treatment-naive patients. This antiviral activity was associated with a decrease in serum levels of liver enzymes in four weeks treatment. Secondly, IMO-2125 is well tolerated and showed a very important safety features compared to Pegasys ® is used in the control group. "

Arbeit said: "We are preparing to begin a 12-week Phase 2 clinical trial of IMO-2125 with ribavirin in treatment naive genotype 1 HCV patients in the second quarter of 2011. We expect to use the data from this study to select doses for subsequent clinical trials of IMO- 2125 in combination with ribavirin and direct action of an antiviral agent....